Max Healthcare Q2 & H1 FY26 Earnings Call Transcript
Max Healthcare's Q2 revenue grew by 21%, EBITDA increased by 23%. Expansion projects are progressing. CGHS revised prices effective October 13th, expecting a favourable impact of over ₹200 crore.
The announcement includes significant financial performance details, capacity expansion updates, and strategic developments, indicating a high potential impact on the company's operations and future prospects.
The company reported strong financial results, including revenue and EBITDA growth, and announced positive developments such as the commissioning of new facilities and resolution of insurance issues.
* Max Healthcare's Q2 revenue grew by 21% year-on-year, and operating EBITDA increased by 23%, marking 20 consecutive quarters of growth. * Existing Units achieved revenue growth of 14% and EBITDA growth of 19%. * A new 268-bed brownfield tower at Nanavati-Max is set to be commissioned this week, and a new 400-bed brownfield tower at Max Smart will be ready for commissioning within the next 30 days. * Divestment of hospitals in Chitta and Anoopshahr was completed in September 2025. * Merger of two wholly-owned subsidiaries resulted in a one-time benefit of ₹149 crore during the quarter. * CGHS revised prices effective October 13th, expecting a favourable impact of over ₹200 crore once fully implemented. * Insurance renewals issues have been resolved. * Network gross revenue stood at ₹2,692 crore, up 21% year-on-year. * Network operating EBITDA stood at ₹694 crore, up 23% year-on-year. * Profit after tax (PAT) for the Network was ₹554 crore, including a one-time tax impact of ₹149 crore. * The Network generated free cash flows of ₹291 crore during the quarter. * International patient revenue reached ₹231 crore, registering a growth of 25% year-on-year. * Max@Home reported revenue of ₹63 crore, reflecting a 20% year-on-year growth, and Max Lab reported revenue of ₹54 crore, reflecting a 16% year-on-year growth. * Expansion projects are progressing at Max Lucknow, Sector 56 Gurgaon, Max Nagpur, Patparganj, Max Vikrant (Saket), Zirakpur, Mohali, Max Vaishali and Thane. The project at Patparganj is expected to be completed by FY'28. * Network gross revenue for H1 FY26 stood at ₹5,266 crore, reflecting a growth of 24% year-on-year. * Overall Network operating EBITDA for H1 FY26 grew by 23% year-on-year to ₹1,308 crore. * The company provided free treatment to approximately 44,000 patients from economically weaker sections of the society, worth ₹61 crore at hospital tariff.
What to do with a filing like this
Max Healthcare Institute Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Max Healthcare Institute Limited. Read the original for the full detail.